Does high-frequency chest wall oscillation therapy have any impact on the infective exacerbations of chronic obstructive pulmonary disease? A randomized controlled single-blind study

Simple item page
dc.contributor.authorGoktalay T.
dc.contributor.authorAkdemir S.E.
dc.contributor.authorAlpaydin A.O.
dc.contributor.authorCoskun A.S.
dc.contributor.authorCelik P.
dc.contributor.authorYorgancioglu A.
dc.date.accessioned2024-07-22T08:18:08Z
dc.date.available2024-07-22T08:18:08Z
dc.date.issued2013
dc.description.abstractObjective: To investigate the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with infective exacerbation. Design: Clinical randomized controlled trial. Setting: Patients received high-frequency chest wall oscillation therapy at the Department of Pulmonology. Subjects: Stage III-IV chronic obstructive pulmonary disease patients hospitalized with acute infective exacerbation who had received high-frequency chest wall oscillation therapy were studied. Interventions: Patients were randomized into two groups, which were classified as I and II. All patients have been treated with bronchodilators, antibiotics, if necessary oxygen and patient education, as part of acute chronic obstructive pulmonary disease exacerbation protocol. Group II patients received additional high-frequency chest wall oscillation therapy. Main measures: Body mass index (B), forced expiratory volume in the first second (O), modified Medical Research Council dyspnea scale (D) and 6-minute walking test (E) (BODE) index, forced expiratory volume in the first second, dyspnea, exercise capacity, oxygenation parameters and hospitalization of duration were recorded at baseline and at three-days and five-days follow-up. Results: From April 2009 to July 2011, a total of 99 patients were assessed for eligibility, 50 patients were enrolled and randomized into two groups. A total of 50 (100%) patients (25 in Group I and 25 in Group II) were followed up for five days. Application of high-frequency chest wall oscillation therapy resulted in no significant advantage in all outcomes (p > 0.05). Mean (SD) baseline BODE index value in Group I was 7.72 (1.76), in Group II was 7.72(1.89) (p = 0.55). On the fifth-day assessment, mean (SD) BODE index value in Group I was 7.24 (1.83), in group II was 6.44 (2.46) (p = 0.18). © The Author(s) 2013.
dc.identifier.DOI-ID10.1177/0269215513478226
dc.identifier.issn14770873
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17208
dc.language.isoEnglish
dc.subjectBody Mass Index
dc.subjectChest Wall Oscillation
dc.subjectDisease Progression
dc.subjectDyspnea
dc.subjectExercise Test
dc.subjectForced Expiratory Volume
dc.subjectHumans
dc.subjectInfection
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectTurkey
dc.subjectChronic obstructive pulmonary disease exacerbations
dc.subjecthigh-frequency chest wall oscillation
dc.subjectpulmonary rehabilitation
dc.subjectbody mass
dc.subjectchest wall oscillation
dc.subjectclassification
dc.subjectcomplication
dc.subjectcontrolled study
dc.subjectdisease course
dc.subjectdyspnea
dc.subjectexercise test
dc.subjectforced expiratory volume
dc.subjecthuman
dc.subjectinfection
dc.subjectprocedures
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectrandomized controlled trial
dc.subjectTurkey
dc.subjectarticle
dc.subjectchest wall oscillation
dc.subjectchronic obstructive lung disease
dc.subjectChronic obstructive pulmonary disease exacerbations
dc.subjectcontrolled clinical trial
dc.subjectdyspnea
dc.subjecthigh-frequency chest wall oscillation
dc.subjectinfection
dc.subjectmethodology
dc.subjectpulmonary rehabilitation
dc.subjectTurkey (republic)
dc.titleDoes high-frequency chest wall oscillation therapy have any impact on the infective exacerbations of chronic obstructive pulmonary disease? A randomized controlled single-blind study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu